Products & Services
Research & Specialties
Custom Peptide Synthesis
Amino Acid Derivatives
Services & Capabilities
Quality & Regulatory
Research Grade Production
Supply & vertical integration
Our vision & strategy
People & culture
Safeguarding the environment
Investors & Media
Reports & Presentations
News & Events
Key figures for capital increase as announced
April 23, 2019
Only available in the German version.
Annual General Meeting approves all Board proposals
Peptide Trends April 2019
Bachem’s Commitment to Sustainability
Bachem intends a capital increase – construction of additional manufacturing site
Bachem’s liraglutide: a high-purity generic for diabetes and weight loss
Certified and essential: our peptides for in vitro diagnostics
Excellent results for the first half-year 2021
Propofol – A Bachem success story
Bachem and Novo Nordisk redesign SPPS for green chemistry
The weight loss drug Liraglutide
Interview with Amy Zhang, Head of Supply Chain at Luye Pharma
What are oligonucleotides?
Somatostatin Analogues Provide Invaluable Therapeutic Options
What are somatostatin and somatostatin analogues?
Bachem innovating through virtual events
Meet Bachem: Pascal Hess, Group Leader Generics – Portfolio
A world market leader from the Basel region – Bachem celebrates 50 years of company history
What are Amino Acids?
Bachem recognized as a winner at the Swiss Biotech Success Stories Awards 2021
What is GMP?
Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson’s Disease?
Meet Bachem: Swetlana Meinhardt, Category Manager